Insider Selling: Psychemedics Co. (NASDAQ:PMD) Director Sells $753,663.80 in Stock

Psychemedics Co. (NASDAQ:PMD) Director Peter Kamin sold 320,708 shares of Psychemedics stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $2.35, for a total value of $753,663.80. Following the transaction, the director now owns 1,499,710 shares in the company, valued at $3,524,318.50. This trade represents a 17.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Peter Kamin also recently made the following trade(s):

• On Tuesday, December 3rd, Peter Kamin purchased 1,409,712 shares of Psychemedics stock. The stock was bought at an average cost of $2.35 per share, for a total transaction of $3,312,823.20.

Psychemedics Stock Down 1.8 %

Shares of PMD stock opened at $2.67 on Friday. Psychemedics Co. has a 12-month low of $1.63 and a 12-month high of $3.93. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $2.38 and a 200-day moving average of $2.31. The company has a market capitalization of $15.73 million, a price-to-earnings ratio of -5.24 and a beta of 0.65.

About Psychemedics

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.